Brief: Roivant Announces Positive Results From PHocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) And Unveils Ongoing Phase 3 PHrontier Study
08/09/2026 11:17
BRIEF-Roivant Announces Positive Results From PHocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) And Unveils Ongoing Phase 3 PHrontier Study Sept 8 (Reuters) - Roivant Sciences Ltd ROIV.O:
ROIVANT ANNOUNCES POSITIVE RESULTS FROM PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) AND UNVEILS ONGOING PHASE 3 PHRONTIER STUDY
ROIVANT SCIENCES LTD - PHOCUS MET ITS PRIMARY ENDPOINT
ROIVANT SCIENCES - MOSLICIGUAT SHOWS LOWER COUGH INCIDENCE THAN PLACEBO IN PHOCUS STUDY
ROIVANT SCIENCES LTD - STUDY ALSO MET ITS SECONDARY ENDPOINTS AT WEEK 16
ROIVANT SCIENCES LTD - MOSLICIGUAT OBSERVED TO BE WELL TOLERATED WITH A FAVORABLE SAFETY PROFILE
Source text: ID:nGNX4GbVPd
Further company coverage: ROIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple